Microbiological and immunological strategies for treatment of inflammatory bowel disease

被引：23

作者：

Steidler, L

机构：

[1] Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium

[2] State Univ Ghent, B-9000 Ghent, Belgium

来源：

MICROBES AND INFECTION | 2001年 / 3卷 / 13期

关键词：

inflammatory bowel disease; immunological therapeutics; delivery; probiotics;

D O I：

10.1016/S1286-4579(01)01476-9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic inflammatory bowel diseases such as Crohn's disease or ulcerative colitis, affect around 1 in every 1 000 individuals in western countries. They probably result from an inappropriate reaction towards the commensal microflora and are currently treated with antiinflammatory drugs or surgery. Novel strategies aim at blocking lymphocyte recruitment and activation, improved targeting of therapeutics and modification of gut microflora. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

引用

收藏

页码：1157 / 1166

页数：10

相关论文

共 98 条

[41] Binding of aflatoxin B1 alters the adhesion properties of Lactobacillus rhamnosus strain GG in a Caco-2 model [J].

Kankaapää, P ;

Tuomola, E ;

El-Nezami, H ;

Ahokas, J ;

Salminen, SJ .

JOURNAL OF FOOD PROTECTION, 2000, 63 (03) :412-414

[42] INFLUENCE OF INFLAMMATORY BOWEL-DISEASE ON INTESTINAL MICROFLORA [J].

KEIGHLEY, MRB ;

ARABI, Y ;

DIMOCK, F ;

BURDON, DW ;

ALLAN, RN ;

ALEXANDERWILLIAMS, J .

GUT, 1978, 19 (12) :1099-1104

[43] Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid:: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation [J].

Kitani, A ;

Fuss, IJ ;

Nakamura, K ;

Schwartz, OM ;

Usui, T ;

Strober, W .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :41-52

[44] Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis [J].

Kruis, W ;

Schutz, E ;

Fric, P ;

Fixa, B ;

Judmaier, G ;

Stolte, M .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :853-858

[45] Promising new agents for the treatment of inflammatory bowel disorders. [J].

Lang K.A. ;

Peppercorn M.A. .

Drugs in R & D, 1999, 1 (3) :237-244

[46] Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity [J].

Liévin, V ;

Peiffer, I ;

Hudault, S ;

Rochat, F ;

Brassart, D ;

Neeser, JR ;

Servin, AL .

GUT, 2000, 47 (05) :646-652

[47] PROBIOTICS - GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS [J].

LILLY, DM ;

STILLWELL, RH .

SCIENCE, 1965, 147 (3659) :747-+

[48] Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions [J].

Liu, ZJ ;

Geboes, K ;

Colpaert, S ;

Overbergh, L ;

Mathieu, C ;

Heremans, H ;

de Boer, M ;

Boon, L ;

D'Haens, G ;

Rutgeerts, P ;

Ceuppens, JL .

JOURNAL OF IMMUNOLOGY, 2000, 164 (11) :6005-6014

[49] Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains [J].

Maassen, CBM ;

van Holten-Neelen, C ;

Balk, F ;

den Bak-Glashouwer, JH ;

Leer, RJ ;

Laman, JD ;

Boersma, WJA ;

Claassen, E .

VACCINE, 2000, 18 (23) :2613-2623

[50] Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease [J].

Macdonald, TT .

GUT, 1998, 42 (04) :460-461

← 1 2 3 4 5 6 7 8 9 10 →